NCT03433677View on ClinicalTrials.gov

A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

February 21, 2018

Primary Completion Date

September 4, 2018

Study Completion Date

September 4, 2018

Conditions
Diabetes Type 1
Interventions
DRUG

LY900014

Administered by CSII

DRUG

Insulin lispro

Administered by CSII

Trial Locations (5)

30318

Atlanta Diabetes Associates, Atlanta

41003

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seville

41009

For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Seville

80045

Barbara Davis Center for Childhood Diabetes, Aurora

93720

Valley Research, Fresno

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03433677 - A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes | Biotech Hunter | Biotech Hunter